Cerevel Therapeutics Holdings, Inc.
CERE
Pozycja w akcjach
#2821
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Cena akcji
$44.96
Ostatnia synchronizacja: 2024-08-01
Kapitalizacja rynkowa
$6.67B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Cerevel Therapeutics Holdings, Inc. (CERE)
Kategoria
Healthcare
Przychody dla Cerevel Therapeutics Holdings, Inc. (CERE)
Przychody w Mar 2024 TTM: $8.25M
Według najnowszych raportów finansowych Cerevel Therapeutics Holdings, Inc., obecny przychód firmy (TTM) wynosi $8.25M. W roku 2022 firma osiągnęła przychód w wysokości 0.00 równa się przychodu z roku 2021, który wynosił 0.00. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Cerevel Therapeutics Holdings, Inc. od 2012 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $8.25M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2015 | $2.72M | 13.14% |
| 2014 | $2.40M | -54.15% |
| 2013 | $5.24M | -2.38% |
| 2012 | $5.37M | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 152,996.05% |
US
|
|
| $2.23B | 26,919.16% |
US
|
|
| $15.74B | 190,832.90% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 72,920.70% |
NL
|
